苏黄止咳胶囊治疗慢性阻塞性肺疾病急性加重期患者的临床疗效研究

Clinical efficacy of the Suhuang Zhike capsule on acute exacerbation of chronic obstructive pulmonary

目的:分析苏黄止咳胶囊治疗慢性阻塞性肺疾病(COPD)患者急性加重期的临床效果。方法:筛选2016年11月1日-2017年10月31日就诊于连山壮族瑶族自治县人民医院重症医学科的COPD患者120例为研究对象,随机分为两组,A组为观察组,B组为对照组,各60例。B患者采取常规治疗方案,A组另每天口服苏黄止咳胶囊1.65g/次,早、中、晚三次,以2个月为1个疗程。治疗结束后进行随访,前12周每4周进行1次,随后每12周进行1次,随访持续时间必须大于48周。结果:B组患者进行常规治疗后,与治疗前相比,FVC、FEV1/FVC和MVV均下降,但其差异不具有统计学意义(P<0.05)。A组患者常规治疗+口服苏黄止咳胶囊治疗后,FVC显著升高,与治疗前相比,差异显著,具有统计学意义(P<0.05);FEV1/FVC、MVV、MMEF也均有所升高,但升幅不显著,无统计学意义(P>0.05);此外,A组患者RV和RV/TLC降低,但无统计学意义。A组与B组比较,为期48周以上的随访观察中,FVC、FEV1/FVC、MVV都显著升高,差异均有统计学意义(P<0.05);治疗后,A组患者的复发再人院次数及再入院率分别为1.67%(1例)、5.00%(3例)、15.00%(9例)、16.67%(10例)、8.33%(5例)和3.33%(2例),B组患者分别为8.33%(5例)、11.67%(7例)、25.00%(15例)、35.00%(21例)、16.67%(10例)和15.00%(9例),两组的差异有统计学意义(P<0.01)。结论:口服苏黄止咳胶囊可以显著改善COPD患者急性加重期的肺功能,减少COPD的再入院率和复发率,疗效显著。

Objective： To analyze the clinical effect of the Suhuang Zhike capsule（ 苏黄止咳胶囊） on acute exacerbation of chronicobstructive pulmonary disease. Methods： A total of 120 COPD patients treated from November 1, 2016 to October 31, 2017 in the department of intensive medicine, Lianshan Zhuang people＇s Hospital, were selected and randomly divided into two groups： group A as the observation group and group B as the control group（60 cases in each group）. Patients in group B were treated with routine treatment, while patients in group A were given a daily dose of the Suhuang Zhike capsule 1.65 g/time, three times a day, and one course as two months. Following up was given after treatment, once every 4 weeks in the first 12 weeks, which was followed by once every 12 weeks, and the duration of follow-up must be longer than 48 weeks. Results： After routine treatment, FVC, FEV1/FVC and MVV in group B were all decreased compared with those before treatment, but the difference was not statistically significant（P〈0.05）. After the routine treatment and the Suhuang Zhike capsule, the FVC was significantly increased in group A, and the difference was statistically significant（P〈0.05）. FEV1/FVC, MVV and MMEF also increased, but the increasing was not significant, with no statistical significance difference（P〈0.05）. In addition, RV and RV/TLC were decreased in group A, but there was no statistical difference. Comparison was made between group A and group B, FVC, FEV1/FVC and MVV were all significantly increased during the follow-up observation over 48 weeks, with statistically significant differences（P〈0.05）. After treatment, the recurrence number and readmission rate in group A was 1.67%（1 case）, 5.00%（3 cases）, 15.00%（9 cases）, 16.67%（10 cases）, 8.33%（5 cases） and 3.33%（2 cases） respectively, while that in group B was 8.33%（5 cases）, 11.67%（7 cases）, 25.00%（15 cases）, 35.00%（21 cases）, 16.67%（10 cases） and 15.00%（9 cases） respectively, the difference was statistically significant（P〈0.01）. Conclusion： Oral administration of the Suhuang Zhike capsule could significantly improve the lung function of acute exacerbation in patients with COPD, and reduce the readmission rate and recurrence rate of COPD.